Act—Elimination of Market Entry Barriers (GN Docket No. 96–113).

Number of petitions filed: 2.

Subject: Implementation of the Non-Accounting Safeguards of Sections 271 and 272 of the Communications Act of 1934, as amended (CC Docket No. 96–149).

Number of petitions filed: 8.

Subject: Implementation of the Telecommunications Act of 1996; Accounting Safeguards Under the Telecommunications Act of 1996. (CC Docket No. 96–150).

Number of petitions filed: 8.

Federal Communications Commission.

William F. Caton,

Acting Secretary.

[FR Doc. 97–6749 Filed 3–17–97; 8:45 am]

BILLING CODE 6712–01–M

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

TIME AND DATE: 12:00 noon, Monday, March 24, 1997.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 2lst Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: March 14, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–6957 Filed 3–14–97; 2:44 pm]

BILLING CODE 6210–01–P

GENERAL SERVICES ADMINISTRATION

Availability of Final Environmental Impact Statement/Environmental Impact; Report for Proposed San Francisco Federal Building, San Francisco, CA

AGENCY: Public Buildings Service, United States General Services Administration.

ACTION: Notice.

SUMMARY: The United States General Services Administration (GSA) hereby gives notice that a joint Final Environmental Impact Statement/ Environmental Impact Report (EIS/EIR) has been prepared and filed with the United States Environmental Protection Agency (EPA) for the proposed construction of a new Federal Building within the City of San Francisco, California, in accordance with the Council of Environmental Quality regulations and the procedural provisions of the National Environmental Policy Act (NEPA). The proposed project involves the construction of a new Federal Building with 161 approximately 475,000 occupiable square feet of space (675,000 gross square feet) and onsite parking spaces. The purpose of this project is (1) to consolidate federal agencies housed in multiple locations in order to increase efficiency and to reduce the amount of government leased space and (2) to house law enforcement agencies that are not suitable as lease tenants. The preferred alternative for this project is the site located at 7th and Mission Streets.

DATES: Submit written comments on the Final EIS/EIR to GSA on or before April 21, 1997.

ADDRESSES: Mail written comments and requests for copies to Ms. Jane Woo, U.S. General Services Administration, Portfolio Management Division (9PT), 450 Golden Gate Avenue, 3rd Floor, San Francisco, California 94102.

FOR FURTHER INFORMATION CONTACT:

Ms. Jane Woo, (415) 522–3487.

(Authority: NEPA, the Environmental Quality Improvement Act of 1970, as amended (42 U.S.C. 4371 *et seq.*), sec. 309 of the Clean Air Act, as amended (42 U.S.C. 7609), and E.O. 11514 (Mar. 5, 1970, as amended by E.O. 11991, May 24, 1977)).

Dated: March 11, 1997.

Kenn N. Kojima,

Regional Administrator (9A).

[FR Doc. 97–6820 Filed 3–17–97; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96E–0504]

Determination of Regulatory Review Period for Purposes of Patent Extension; BAYTRIL®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for BAYTRIL® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A testing phase and an approval phase. For animal drug products, the testing phase begins on the earlier date when either a major environmental effects test was initiated for the drug or when an exemption under section 512(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(j)) became effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the animal drug product and continues until FDA grants permission to market the drug product. Although only a portion of a